Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Zaleplon
Capsules, 10 mg, to Sonata ® Capsules, 10 mg (Jones Pharma) under fed conditions using a
single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design